Interaction Checker

Ruksolitinib etkileşimleri

JAK inhibitörü sınıfından Ruksolitinib (Jakafi, Opzelura) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 75 belgelenmiş etkileşim var: 10 majör, 65 orta, 0 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 0 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Etikete göre etkileşimler

Majör etkileşimler (10)

  • AbataseptimmünosüpresanMajör

    Additionally, concomitant use of ORENCIA with other biologic RA/PsA therapy or JAK inhibitors is not recommended. (Abatasept etiketi, Uyarılar ve önlemler)

  • AbrositinibJAK inhibitörüMajör

    Major Adverse Cardiovascular Events (MACE) Another JAK inhibitor has increased the risk of MACE, including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. (Ruksolitinib etiketi, Uyarılar ve önlemler)

  • AdalimumabimmünosüpresanMajör

    Major Adverse Cardiovascular Events (MACE) Another JAK inhibitor has increased the risk of MACE, including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. (Ruksolitinib etiketi, Uyarılar ve önlemler)

  • BarisitinibJAK inhibitörüMajör

    Major Adverse Cardiovascular Events (MACE) Another JAK inhibitor has increased the risk of MACE, including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. (Ruksolitinib etiketi, Uyarılar ve önlemler)

  • EtanerseptimmünosüpresanMajör

    Major Adverse Cardiovascular Events (MACE) Another JAK inhibitor has increased the risk of MACE, including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. (Ruksolitinib etiketi, Uyarılar ve önlemler)

  • Flukonazolazol antifungalMajör

    Fluconazole: Avoid concomitant use with fluconazole doses greater than 200 mg. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • İnfliksimabimmünosüpresanMajör

    Major Adverse Cardiovascular Events (MACE) Another JAK inhibitor has increased the risk of MACE, including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. (Ruksolitinib etiketi, Uyarılar ve önlemler)

  • RitlesitinibJAK inhibitörüMajör

    Major Adverse Cardiovascular Events (MACE) Another JAK inhibitor has increased the risk of MACE, including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. (Ruksolitinib etiketi, Uyarılar ve önlemler)

  • TofasitinibimmünosüpresanMajör

    Major Adverse Cardiovascular Events (MACE) Another JAK inhibitor has increased the risk of MACE, including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. (Ruksolitinib etiketi, Uyarılar ve önlemler)

  • UpadasitinibimmünosüpresanMajör

    Major Adverse Cardiovascular Events (MACE) Another JAK inhibitor has increased the risk of MACE, including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which JAKAFI/JAKAFI XR is not indicated. (Ruksolitinib etiketi, Uyarılar ve önlemler)

Orta düzey etkileşimler (65)

  • AmiodaronantiaritmikOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • AprepitantCYP3A4 inhibitörüOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • ArmodafinilMSS uyarıcısıOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • AtazanavirantiretroviralOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • BosentanCYP3A4 indükleyicisiOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • DarunavirantiretroviralOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • Darunavir ve kobisistatantiretroviralOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • Deferasiroksdemir takviyesiOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • DeksametazonkortikosteroidOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • Diltiazemkalsiyum kanal blokeriOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • DronedaronantiaritmikOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • EfavirenzantiretroviralOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • Efavirenz, lamivudin ve tenofovirantiretroviralOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • Elvitegravir, kobisistat, emtrisitabin ve tenofovirantiretroviralOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • Eritromisinmakrolid antibiyotikOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • EslikarbazepinantikonvülsanOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • EtravirinantiretroviralOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • EverolimusimmünosüpresanOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • FenitoinantikonvülsanOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • FenobarbitalbarbitüratOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • Fentermin ve topiramatMSS uyarıcısıOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • FosamprenavirantiretroviralOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • FosaprepitantCYP3A4 inhibitörüOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • FosfenitoinantikonvülsanOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • GriseofulvinantifungalOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • İmatinibCYP3A4 inhibitörüOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • İtrakonazolazol antifungalOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • İvakaftorCYP3A4 inhibitörüOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • İzoniazidantibiyotikOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • KarbamazepinantikonvülsanOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • Ketokonazolazol antifungalOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • Klaritromisinmakrolid antibiyotikOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • KlobazambenzodiazepinOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • LenakapavirantiretroviralOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • Lopinavir ve ritonavirantiretroviralOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • LorlatinibCYP3A4 indükleyicisiOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • MifepristonCYP3A4 inhibitörüOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • Mirabegronbeta adrenerjik agonistOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • MitapivatCYP3A4 indükleyicisiOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • MitotanCYP3A4 indükleyicisiOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • ModafinilMSS uyarıcısıOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • Nafsilinpenisilin antibiyotikOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • NefazodonantidepresanOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • NevirapinantiretroviralOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • Nirmatrelvir ve ritonavirantiviralOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • OkskarbazepinantikonvülsanOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • PalbosiklibCYP3A4 inhibitörüOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • PerampanelantikonvülsanOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • Posakonazolazol antifungalOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • PrimidonantikonvülsanOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • RanolazinQT aralığını uzatan ilaçOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • RifabutinantibiyotikOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • RifampisinantibiyotikOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • RifapentinantibiyotikOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • RitonavirantiretroviralOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • SenobamatantikonvülsanOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • SiklosporinimmünosüpresanOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • SimetidinH2 blokeriOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • Suvoreksantsedatif-hipnotikOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • SuzetrijinCYP3A4 indükleyicisiOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • Tikagrelorantitrombosit ilaçOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • TopiramatantikonvülsanOrta

    Strong CYP3A4 Inducers Concomitant use of JAKAFI/JAKAFI XR with strong CYP3A4 inducers may decrease ruxolitinib exposure [ see Clinical Pharmacology ( 12.3 )] , which may reduce efficacy of JAKAFI/JAKAFI XR. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • Tütün ve sigaraTütün ve kenevirOrta

    Secondary Malignancies: Monitor for development of secondary malignancies, particularly in patients who are current or past smokers. (Ruksolitinib etiketi, Uyarılar ve önlemler)

  • Verapamilkalsiyum kanal blokeriOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

  • Vorikonazolazol antifungalOrta

    Strong CYP3A4 Inhibitors: Reduce, interrupt, or discontinue JAKAFI/JAKAFI XR doses as recommended except in patients with acute or chronic graft-versus-host-disease. (Ruksolitinib etiketi, İlaç etkileşimleri)

Kullandığınız her şeyi Ruksolitinib ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.